1416320-49-4

Upstream product

• 1365037-86-0 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-4-yl)-1H-pyrazole-3-carboxamide 
• 1365037-83-7 tert-butyl 4-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-amido]piperidine-1-carboxylate 
• 162758-35-2 rimonabant acid 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 1416320-59-6 4-nitrophenyl-4-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-amido]piperidine-1-carboxylate 
• 67-63-0 isopropyl alcohol 

Relevant academic research and scientific papers

Pyrazole antagonists of the CB1 receptor with reduced brain penetration

Type 1 cannabinoid receptor (CB1) antagonists might be useful for treating obesity, liver disease, metabolic syndrome, and dyslipidemias. Unfortunately, inhibition of CB1 in the central nervous system (CNS) produces adverse effects, including depression,

PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS

The invention provides compounds capable of acting as antagonists at cannabanoid receptors according to the following formula: Such compounds may be used to treat conditions for which the cannabinoid receptor system has been implicated, such as obesity, liver disease, diabetes, pain, and inflammation.